Takeda Pharmaceutical Company and partner, Zinfandel Pharmaceuticals, have begun Phase III trial, also known as TOMMORROW, to assess investigational low dose pioglitazone.
In the study, a genetic-based biomarker risk assignment algorithm to predict risk of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) within a five-year period will be assessed.
Go deeper with GlobalData
The investigational agent’s efficacy in delaying the onset of MCI due to AD in cognitively normal individuals at high risk as determined by the risk assignment algorithm will also be evaluated.
Apolipoprotein E (APOE) and TOMM40 genotypes and age are included in the risk assignment algorithm.
Zinfandel chief executive officer Dr Allen Roses said to date, there have been a number of avenues investigated with the goal of altering the course of Alzheimer’s disease but results have been unsuccessful.
"This is why the TOMMORROW trial is important. The potential to identify an individual’s risk for developing MCI due to AD warrants further investigation," Roses added.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataApproximately 5,800 cognitively normal individuals aged 65-83 at 50 centres across the globe will be randomised into the multicentre, double-blind, placebo-controlled study.
The primary endpoint for the risk assignment algorithm is time to diagnosis of MCI due to AD for placebo-treated, high-risk subjects compared to placebo-treated, low-risk subjects.
For AD-4833, the primary objective is to estimate the efficacy of AD-4833 against placebo in delaying the onset of MCI due to AD in cognitively normal individuals assessed as ‘high risk’ based on the risk assignment algorithm.
The time to diagnosis of MCI due to AD for AD-4833-treated subjects compared to placebo-treated subjects in the high-risk stratum is the primary endpoint.
Key secondary objectives include the effect of AD-4833 against placebo on the progression of cognitive decline and comparison of the effects of AD-4833 opposed to placebo on functional decline and instrumental activities of daily living.
Takeda central nervous system development therapeutic area head Dr Stephen Brannan said: "AD-4833 is a member of a class of drugs known as PPAR (peroxisome proliferator-activated receptor)-gamma agonists, which available data show may have a beneficial role in delaying symptoms of MCI due to AD."
Image: Takeda Midosuji Building, headquarters of Takeda Pharmaceutical Company, in Chuo-ku, Osaka, Japan. Photo: J o.
